Company: PACB
Filing Date: 2025-03-17
Form Type: 10-K
Source: 0001299130-25-000061
Chunk: 128

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-03-17
Form: 10-K
Item: Item 1
Chunk 128
---
651)Deferred revenue (2,108)(10,420)(3,734)Operating lease liabilities(11,920)(8,759)(7,724)Contingent consideration liability— (14,882)— Other liabilities (4,612)2,449 887 Net cash used in operating activities (206,058)(259,173)(263,211)Cash flows from investing activitiesPurchase of property and equipment (6,188)(8,843)(16,750)Purchase of intangible assets— — (179)Cash paid for purchases of acquired entities, net of cash acquired— (102)— Purchase of investments (498,635)(756,567)(442,788)Sales of investments 34,856 595 — Maturities of investments 593,971 769,521 575,800 Net cash provided by investing activities 124,004 4,604 116,083 Cash flows from financing activitiesProceeds from issuance of common stock under equity offerings, net of issuance costs— 189,200 — Proceeds from issuance of common stock from equity plans7,703 15,319 11,230 Payment of debt issuance costs— (7,375)— Payment of contingent consideration— (86,411)— 

Fiscal 2024 Form 10-K88

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.CONSOLIDATED STATEMENTS OF CASH FLOWSPayments made in conjunction with convertible notes exchange(50,200)— — Notes payable principal payoff (490)(1,842)(1,608)Net cash (used in) provided by financing activities (42,987)108,891 9,622 Net decrease in cash, cash equivalents, and restricted cash(125,041)(145,678)(137,506)Cash, cash equivalents, and restricted cash at beginning of period 182,633 328,311 465,817 Cash, cash equivalents, and restricted cash at end of period $57,592 $182,633 $328,311 Cash and cash equivalents at end of period 55,370 179,911 325,089 Restricted cash at end of period 2,222 2,722 3,222 Cash, cash equivalents, and restricted cash at end of period $57,592 $182,633 $328,311  Supplemental disclosure of